KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other financing activities (2016 - 2025)

Pfizer (PFE) has disclosed Other financing activities for 17 consecutive years, with -$43.0 million as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to -$43.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$458.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$458.0 million for FY2025, 2.35% up from the prior year.
  • Other financing activities for Q4 2025 was -$43.0 million at Pfizer, down from -$38.0 million in the prior quarter.
  • The five-year high for Other financing activities was $154.0 million in Q3 2022, with the low at -$610.0 million in Q2 2021.
  • Average Other financing activities over 5 years is -$198.6 million, with a median of -$140.0 million recorded in 2023.
  • The sharpest move saw Other financing activities skyrocketed 302.0% in 2021, then tumbled 1129.73% in 2024.
  • Over 5 years, Other financing activities stood at -$185.0 million in 2021, then plummeted by 84.86% to -$342.0 million in 2022, then skyrocketed by 94.74% to -$18.0 million in 2023, then crashed by 2427.78% to -$455.0 million in 2024, then soared by 90.55% to -$43.0 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$43.0 million, -$38.0 million, and -$21.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.